Open Access
Subscription Access
Understanding Mucolytics: Breaking Down the Role of Drugs in Respiratory Health
Abstract
Mucolytics are a class of drugs that playva major role especially vin managing respiratory conditions by targeting particularly mucus in the airways. One of the most commonly used mucolytics is N _ acetyl cysteine (NAC) which performs s by breaking the disulfide bonds within the mucus proteins. This process helps in decreasing the viscosity of the mucus, permitting it to be cleared more in an effective manner through cough or other natural mechanisms. In chronic bronchitis an additional mucolytics such as bromohexine and ambroxol are used. These drugs plays role by activating the production of thinner mucous enhancing eadier expectoration. In chronic obstructive pulmonary disease ( COPD ), mucolytics decrease symptoms and enhance lung functional activities. Cystic fibrosis, a genetic disorder that leads to thick and sticky mucus production, is another condition namely where mucolytics play a critical role. Finally virbis concluded that mucolytics represent an exceptiona exceptional class of drugs in the management of respiratory conditions manifested by excessive mucus production.
References
Sadowska, A. M., Verbraecken, J., Darquennes, K., & De Backer, W. A. (2006). Role of N-acetylcysteine in the management of COPD. International journal of chronic obstructive pulmonary disease, 1(4), 425-434.2.
Hooper, C., & Calvert, J. (2008). The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease. International journal of chronic obstructive pulmonary disease, 3(4), 659-669.
Sun, L., Tang, L., Xu, Y., Wang, S., Li, Y., & Kang, J. (2010). The effect and mechanism of action of carbocysteine on airway bacterial load in rats chronically exposed to cigarette smoke. Respirology, 15(7), 1064-1071.
Negro, R. W. D. (2008). Erdosteine: antitussive and anti-inflammatory effects. Lung, 186(Suppl 1), 70-73.
Dechant, K. L., & Noble, S. (1996). Erdosteine. Drugs, 52(6), 875-81.
Bryson, H. M., & Sorkin, E. M. (1994). Dornase alfa: a review of its pharmacological properties and therapeutic potential in cystic fibrosis. Drugs, 48, 894-906.
Rubin, B. K. (2010). Air and soul: the science and application of aerosol therapy. Respiratory care, 55(7), 911-921.
Ziment, I. (1986). Acetylcysteine: a drug with an interesting past and a fascinating future. Respiration, 50(Suppl 1), 26-30.
Holdiness, M. R. (1991). Clinical pharmacokinetics of N-acetylcysteine. Clinical pharmacokinetics, 20, 123-134.
Kortsalioudaki, C., Taylor, R. M., Cheeseman, P., Bansal, S., Mieli‐Vergani, G., & Dhawan, A. (2008). Safety and efficacy of N‐acetylcysteine in children with non‐acetaminophen‐induced acute liver failure. Liver transplantation, 14(1), 25-30.
Nasr, S. Z., Kuhns, L. R., Brown, R. W., Hurwitz, M. E., Sanders, G. M., & Strouse, P. J. (2001). Use of computerized tomography and chest x‐rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study. Pediatric pulmonology, 31(5), 377-382.
Miller, L. F., & Rumack, B. H. (1983). Clinical safety of high oral doses of acetylcysteine. Semin Oncol, 10(1 Suppl 1), 76-85.
Mahmoudi, G. A., Astaraki, P., Mohtashami, A. Z., & Ahadi, M. (2015). N-acetylcysteine overdose after acetaminophen poisoning. International medical case reports journal, 65-69.
Cascella, M., Rajnik, M., Cuomo, A., Dulebohn, S. C., & Di Napoli, R. (2020). StatPearls Publishing. Treasure Island (FL).
Aitken, M. L., Burke, W., McDonald, G., Shak, S., Montgomery, A. B., & Smith, A. (1992). Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis: a phase 1 study. Jama, 267(14), 1947-1951.
Mohler, M.A.R.J.O.R.I.E., Cook, J.E.N.N.I.F.E.R., Lewis, D.E.A.F., Moore, J.E.R.O.M.E., Sinicropi, D.O.M.I.N.I.C.K., Championsmith, A.N.T.O.N.I.O., ... & Mordenti, J.O.Y.C.E. (1993). Altered pharmacokinetics of recombinant human deoxyribonuclease in rats due to the presence of a binding protein. Drug metabolism and disposition, 21(1), 71-75.
Green, J. D. (1994). Pharmaco-toxicological expert report Pulmozyme rhDNase Genentech, Inc. Human & experimental toxicology, 13, S1-S42.
Unverferth, D. V., Leier, C. V., Balcerzak, S. P., & Hamlin, R. L. (1985). Usefulness of a free radical scavenger in preventing doxorubicin-induced heart failure in dogs. The American journal of cardiology, 56(1), 157-161.
Kanter, M. Z. (2006). Comparison of oral and iv acetylcysteine in the treatment of acetaminophen poisoning. American Journal of Health-System Pharmacy, 63(19), 1821-1827.
Ernst, M. M., Johnson, M. C., & Stark, L. J. (2010). Developmental and psychosocial issues in cystic fibrosis. Child and Adolescent Psychiatric Clinics, 19(2), 263-283.
Cazzola, M., Calzetta, L., Page, C., Jardim, J., Chuchalin, A. G., Rogliani, P., & Matera, M. G. (2015). Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. European Respiratory Review, 24(137), 451-461.
Yang, C., & Montgomery, M. (2021). Dornase alfa for cystic fibrosis. Cochrane Database of Systematic Reviews, (3).
Zeng, Z., Yang, D., Huang, X., & Xiao, Z. (2017). Effect of carbocisteine on patients with COPD: a systematic review and meta-analysis. International Journal of Chronic Obstructive Pulmonary Disease, 2277-2283.
Dal Negro, R. W., Wedzicha, J. A., Iversen, M., Fontana, G., Page, C., Cicero, A. F., ... & Calverley, P. M. (2017). Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. European Respiratory Journal, 50(4).
Refbacks
- There are currently no refbacks.